
Scott C Woller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3603417/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.8	4,060
2	The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. Annals of Internal Medicine, 2015, 163, S1-S40.	3.9	403
3	Antithrombotic Therapy for VTE Disease. Chest, 2021, 160, e545-e608.	0.8	357
4	Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. Journal of Thrombosis and Thrombolysis, 2016, 41, 154-164.	2.1	230
5	Risk of Symptomatic DVT Associated With Peripherally Inserted Central Catheters. Chest, 2010, 138, 803-810.	0.8	221
6	A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). Circulation, 2012, 125, 1997-2005.	1.6	217
7	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2017, 318, 1115.	7.4	198
8	Risk of Deep Vein Thrombosis Following a Single Negative Whole-Leg Compression Ultrasound. JAMA - Journal of the American Medical Association, 2010, 303, 438.	7.4	169
9	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 2014, 11, 2206-2213.	0.7	130
10	Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. American Journal of Cardiology, 2016, 118, 210-214.	1.6	123
11	Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thrombosis and Haemostasis, 2012, 108, 1097-1108.	3.4	114
12	Radiation and Chest CT Scan Examinations. Chest, 2012, 142, 750-760.	0.8	110
13	Derivation and Validation of a Simple Model to Identify Venous Thromboembolism Risk in Medical Patients. American Journal of Medicine, 2011, 124, 947-954.e2.	1.5	103
14	Reduction of Peripherally Inserted Central Catheter-Associated DVT. Chest, 2013, 143, 627-633.	0.8	89
15	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. Journal of the American College of Radiology, 2014, 11, 378-383.	1.8	86
16	Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 239-247.	1.7	85
17	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2126-2137.	3.8	84
18	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus, 2020, 29, 1571-1593.	1.6	80

#	Article	IF	CITATIONS
19	The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities. American Journal of Medicine, 2015, 128, 986-993.e1.	1.5	73
20	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood, 2020, 135, 1788-1810.	1.4	73
21	Adherence to PIOPED II Investigators' Recommendations for Computed Tomography Pulmonary Angiography. American Journal of Medicine, 2013, 126, 36-42.	1.5	70
22	Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization. Chest, 2018, 154, 249-256.	0.8	60
23	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Advances, 2022, 6, 1661-1670.	5.2	56
24	Atrial Fibrillation Patients Treated With Longâ€Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Longâ€Term Warfarin for Other Indications. Journal of the American Heart Association, 2016, 5, .	3.7	43
25	Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin. American Heart Journal, 2017, 188, 93-98.	2.7	41
26	Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 192-192.	1.7	41
27	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Longâ€Term Risk of Dementia. Journal of Cardiovascular Electrophysiology, 2015, 26, 1180-1186.	1.7	40
28	The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) initiative: A summary and review of peripherally inserted central catheter and venous catheter appropriate use. Journal of Hospital Medicine, 2016, 11, 306-310.	1.4	36
29	Assessment of the Safety and Efficiency of Using an Age-Adjusted D-dimer Threshold to Exclude Suspected Pulmonary Embolism. Chest, 2014, 146, 1444-1451.	0.8	32
30	Atypical Calciphylaxis in a Patient Receiving Warfarin Then Resolving With Cessation of Warfarin and Application of Hyperbaric Oxygen Therapy. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 345-350.	1.7	29
31	Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 665-672.	1.7	29
32	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. Journal of the American College of Radiology, 2016, 13, R18-R24.	1.8	28
33	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
34	Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study. Clinical Cardiology, 2019, 42, 506-512.	1.8	18
35	Venous Thromboembolism in Critically III Medical Patients Receiving Chemoprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 265-273.	1.7	16
36	Computer surveillance of patients at high risk for and with venous thromboembolism. AMIA Annual Symposium proceedings, 2010, 2010, 217-21.	0.2	16

#	Article	IF	CITATIONS
37	Electronic Alerts, Comparative Practitioner Metrics, and Education Improves Thromboprophylaxis and Reduces Thrombosis. American Journal of Medicine, 2016, 129, 1124.e17-1124.e26.	1.5	15
38	Comparative thrombosis risk of vascular access devices among critically ill medical patients. Thrombosis Research, 2018, 172, 54-60.	1.7	15
39	Natural Language Processing Performance for the Identification of Venous Thromboembolism in an Integrated Healthcare System. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110131.	1.7	15
40	Weight-based enoxaparin dosing and deep vein thrombosis in hospitalized trauma patients: A double-blind, randomized, pilot study. Surgery, 2018, 164, 144-149.	1.9	14
41	Age-adjusted versus clinical probability-adjusted D-dimer to exclude pulmonary embolism. Thrombosis Research, 2018, 167, 15-19.	1.7	14
42	Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARMâ€DVT): Methods of a prospective singleâ€arm management study. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 340-348.	2.3	14
43	Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Advances, 2020, 4, 2557-2566.	5.2	14
44	Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: A prospective randomized trial. Journal of Trauma and Acute Care Surgery, 2021, 90, 787-796.	2.1	14
45	Computerized Clinical Decision Support Improves Warfarin Management and Decreases Recurrent Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 197-203.	1.7	13
46	Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 9-12.	2.3	13
47	Electronic alerts, comparative practitioner metrics, and education improve thromboprophylaxis and reduce venous thrombosis in community hospitals. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 481-489.	2.3	12
48	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Journal of Thrombosis and Haemostasis, 2022, 20, 1910-1919.	3.8	12
49	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2019, 322, 834.	7.4	9
50	The use of a fixed high sensitivity to evaluate five D-dimer assays' ability to rule out deep venous thrombosis: a novel approach. British Journal of Haematology, 2005, 131, 341-347.	2.5	8
51	Withholding Anticoagulation Following a Single Negative Whole-Leg Ultrasound in Patients at High Pretest Probability for Deep Vein Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 79-85.	1.7	8
52	Treatment of Chronic Lead Toxicity With Succimer. American Journal of Forensic Medicine and Pathology, 2011, 32, 236-238.	0.8	7
53	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 209S-216S.	1.7	6
54	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2245-2252.	3.8	6

#	Article	IF	CITATIONS
55	Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism. Chest, 2018, 153, 1153-1159.	0.8	5
56	Diagnostic yield of pulmonary embolism testing in patients presenting to the emergency department with syncope. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 263-268.	2.3	5
57	Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. American Journal of Emergency Medicine, 2021, 41, 80-83.	1.6	5
58	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. American Journal of Cardiology, 2021, 153, 58-64.	1.6	5
59	Intermittent pneumatic compression in patients with stroke. Lancet, The, 2013, 382, 484-486.	13.7	4
60	The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 75-82.	1.6	4
61	Postâ€discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12560.	2.3	4
62	Comparative Frequency of Venous Thromboembolism in Patients Admitted to the Hospital with SARS-CoV-2 Infection versus Community-acquired Pneumonia. Annals of the American Thoracic Society, 2022, 19, 1233-1235.	3.2	4
63	Hepatic epithelioid hemangioendothelioma presenting as liver infarction. Clinical Gastroenterology and Hepatology, 2005, 3, A20.	4.4	3
64	Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study. Cardiology Research and Practice, 2015, 2015, 1-10.	1.1	3
65	Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation. European Heart Journal, 2019, 40, 1538-1540.	2.2	2
66	Predicting postdischarge hospitalâ€associated venous thromboembolism among medical patients using a validated mortality risk score derived from common biomarkers. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 872-878.	2.3	2
67	Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 231-241.	2.1	1
68	Timing of parenteral anticoagulation after thrombolysis for the treatment of pulmonary embolism. Thrombosis Research, 2020, 195, 58-61.	1.7	1
69	Choosing ultrasound technique for suspected deep vein thrombosis: which is best?. Quantitative Imaging in Medicine and Surgery, 2020, 10, 1418-1421.	2.0	1
70	Safety of Excluding Suspected Deep Vein Thrombosis with a Single Whole-Leg Compression Ultrasound: Systematic Review and Meta-Analysis Blood, 2009, 114, 243-243.	1.4	1
71	Abstract 11662: Obesity Does Not Increase Venous Thromboembolism in Hospitalized Medical Patients Upon Multivariate Analysis. Circulation, 2014, 130, .	1.6	1
72	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort. BMJ Open, 2022, 12, e053864.	1.9	1

#	Article	IF	CITATIONS
73	Physician perceptions and use of reducedâ€dose direct oral anticoagulants for extended phase venous thromboembolism treatment. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12740.	2.3	1
74	Guideline-Based Utilization Of CT Pulmonary Angiography For Suspected Pulmonary Embolism. , 2011, , .		0
75	Ultrasound of the Whole Arm to Manage Suspected Upper-Extremity Deep Venous Thrombosis. JAMA Internal Medicine, 2015, 175, 1227.	5.1	0
76	Use of signals and systems engineering to improve the safety of warfarin initiation. Journal of Thrombosis and Thrombolysis, 2016, 42, 529-533.	2.1	0
77	Abstract 13426: Percent Time With a Supratherapeutic Inr in Atrial Fibrillation Patients Using an Antiplatelet Agent is Associated With Long-term Risk of Dementia. Circulation, 2014, 130, .	1.6	0
78	THROMBOEMBOLISM-RISK-BASED ALGORITHM DECREASES ANTICOAGULATION RATES AND BLEEDING RISK AFTER LIVER TRANSPLANTATION. Transplantation, 2020, 104, S480-S481.	1.0	0